ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM)

Pharmaceutical

ImmuPharma

Tim has 30 years of experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner-Lambert, Wellcome, and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a Ph.D. in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Tim Franklin

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Sébastien R. Goudreau

Lisa Baderoon is the current Non-Executive Director & Head of Investor Relations at [ImmuPharma](/org/immupharma). Prior to their current position, Lisa held the position of Head of Financial PR and Investor Relations at dotDigital Group plc from April 2012 to November 2017. Lisa was responsible for key aspects of dotDigital's transition from a small email marketing company to a global e-commerce business, including share price accretion, third party broker coverage, new institutional brokers on a global basis, strong media following, and proactive and inventive shareholder interaction including workshops and technology symposiums. Lisa has also held the position of Partner at Buchanan Communications Ltd from September 1990 to December 2011.

Lisa Baderoon went to John Newnham College.

Lisa Baderoon works with Jean-Paul Briand - Research Director at [CNRS](/org/cnrs) & Co-founder of [ImmuPharma](/org/immupharma) France, Tracy Weimar - Vice President, Operations & Finance, and José Courty - Research Director at [CNRS](/org/cnrs). Lisa Baderoon reports to Dimitri F Dimitriou, Chief Executive Officer & Co-Founder.

Lisa Baderoon

Sanjeev has over 25 years of healthcare and international management experience. Sanjeev was formerly CEO of Advanced Oncotherapy Plc, a specialist cancer radiotherapy business listed on AIM. During his leadership, Sanjeev raised over $100m and developed and secured partnerships in the USA, EU, China, Singapore, India, Australia, Asia, and South America. Formerly, Sanjeev had a number of leadership roles in several global clinical trials at Pfizer and was head of Europe Regulatory and Medical at Reckitt Benckiser.

Formerly Sanjeev trained and worked as an orthopedic surgeon in the NHS and various Third World countries. Sanjeev has a medical degree from Trinity College, Cambridge, and an MBA from INSEAD.

Sanjeev Pandya

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became the Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Laura Mauran-Ambrosino

Sylviane Muller

Tim McCarthy is the CEO at [ImmuPharma](/org/immupharma). Prior to this, they were with Peptide Therapeutics plc where they served as Co-Founder and Finance Director. Peptide Therapeutics was a biopharmaceutical company that was formed in 1993 with a focus on discovering and developing drugs in the area of inflammation and vaccines. The company was listed on the [London Stock Exchange](/org/london-stock-exchange-group) in 1995 and later acquired Oravax in the USA. In 2008, the company was sold to sanofi-aventis for £276 million.

After graduating from college, Tim McCarthy pursued a Master of Business Administration (MBA) at Cranfield School of Management. Tim then went on to get their FCCA from the Chartered Association of Certified Accountants.

ImmuPharma

Org chart

Teams

Board of Directors

Leadership Team

Founding Team

CEO and Executive Team

Discover similar companies